Sun Jian, Gu Yihong, Lin Wei, Luo Linjuan, Li Wei, He Jinrong, Zhan Zishun, Tang Juan
Department of Nephrology and Rheumatology, Third Xiangya Hospital, Central South University, Changsha, China.
Clinical Research Center for Critical Kidney Disease in Hunan Province, Changsha, China.
Ren Fail. 2025 Dec;47(1):2515532. doi: 10.1080/0886022X.2025.2515532. Epub 2025 Jun 12.
To investigate protein kinase Lyn expression in patients with systemic lupus erythematosus (SLE) or lupus nephritis (LN) and its association with clinical markers.
Sixty-one inpatients with SLE were categorized into low SLE Disease Activity Index (SLEDAI) group (SLEDAI < 6, = 32) and high SLEDAI group (SLEDAI ≥ 6, = 29). Thirty volunteers served as healthy controls (HC). SLE patients were further divided into non-LN ( = 31) and LN ( = 30) groups. Lyn mRNA and protein levels in peripheral blood mononuclear cells (PBMCs) were analyzed and correlations between Lyn expression and SLEDAI, clinical parameters were examined. Renal biopsies from LN ( = 24) were collected for immunohistochemical analysis of Lyn level.
Compared to the HC group, SLE patients exhibited a decline in both Lyn mRNA and protein expression in PBMCs, with significant downregulation in the high SLEDAI group versus the low SLEDAI group and a notable reduction in the LN group relative to the non-LN group. Lyn levels negatively correlated with SLEDAI and 24-hour urine protein (24h-U-pro) while positively correlated with serum C3, C4, hemoglobin, and albumin. Multiple linear regression indicated an independent association between Lyn mRNA and SLEDAI. ROC curve analysis suggested Lyn as a reliable predictor for SLE, LN, and lupus activity, with histopathological examination revealing that decreased Lyn expression correlated negatively with the renal pathology index ( = -0.8016, = 0.0016).
The protein kinase Lyn was inversely associated with disease activity, albuminuria level and renal pathology activity in SLE and may be a promising biomarker for assessing LN disease activity.
研究蛋白激酶Lyn在系统性红斑狼疮（SLE）或狼疮性肾炎（LN）患者中的表达及其与临床指标的关联。
61例SLE住院患者被分为低SLE疾病活动指数（SLEDAI）组（SLEDAI<6，n = 32）和高SLEDAI组（SLEDAI≥6，n = 29）。30名志愿者作为健康对照（HC）。SLE患者进一步分为非LN组（n = 31）和LN组（n = 30）。分析外周血单个核细胞（PBMC）中Lyn mRNA和蛋白水平，并检测Lyn表达与SLEDAI、临床参数之间的相关性。收集24例LN患者的肾活检组织进行Lyn水平的免疫组化分析。
与HC组相比，SLE患者PBMC中Lyn mRNA和蛋白表达均下降，高SLEDAI组相对于低SLEDAI组显著下调，LN组相对于非LN组明显降低。Lyn水平与SLEDAI和24小时尿蛋白（24h-U-pro）呈负相关，与血清C3、C4、血红蛋白和白蛋白呈正相关。多元线性回归表明Lyn mRNA与SLEDAI之间存在独立关联。ROC曲线分析表明Lyn是SLE、LN和狼疮活动的可靠预测指标，组织病理学检查显示Lyn表达降低与肾病理指数呈负相关（r = -0.8016，P = 0.0016）。
蛋白激酶Lyn与SLE的疾病活动、蛋白尿水平和肾病理活动呈负相关，可能是评估LN疾病活动的有前景的生物标志物。
